Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry

Andrea O Y Luk, Wing-Yee So, Ronald C W Ma, Alice P S Kong, Risa Ozaki, Vanessa S W Ng, Linda W L Yu, Winnie W Y Lau, Xilin Yang, Francis C C Chow, Juliana C N Chan, Peter C Y Tong, Hong Kong Diabetes Registry, Andrea O Y Luk, Wing-Yee So, Ronald C W Ma, Alice P S Kong, Risa Ozaki, Vanessa S W Ng, Linda W L Yu, Winnie W Y Lau, Xilin Yang, Francis C C Chow, Juliana C N Chan, Peter C Y Tong, Hong Kong Diabetes Registry

Abstract

Objective: Type 2 diabetes is the leading cause of end-stage renal disease worldwide. Aside from hyperglycemia and hypertension, other metabolic factors may determine renal outcome. We examined risk associations of metabolic syndrome with new onset of chronic kidney disease (CKD) in 5,829 Chinese patients with type 2 diabetes enrolled between 1995 and 2005.

Research design and methods: Metabolic syndrome was defined by National Cholesterol Education Program Adult Treatment Panel III criteria with the Asian definition of obesity. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease formula modified for the Chinese population. New onset of CKD was defined as eGFR <60 ml/min per 1.73 m(2) at the time of censor. Subjects with CKD at baseline were excluded from the analysis.

Results: After a median follow-up duration of 4.6 years (interquartile range: 1.9-7.3 years), 741 patients developed CKD. The multivariable-adjusted hazard ratio (HR) of CKD was 1.31 (95% CI 1.12-1.54, P = 0.001) for subjects with metabolic syndrome compared with those without metabolic syndrome. Relative to subjects with no other components of metabolic syndrome except for diabetes, those with two, three, four, and five metabolic syndrome components had HRs of an increased risk of CKD of 1.15 (0.83-1.60, P = 0.407) 1.32 (0.94-1.86, P = 0.112), 1.64 (1.17-2.32, P = 0.004), and 2.34 (1.54-3.54, P < 0.001), respectively. The metabolic syndrome traits of central obesity, hypertriglyceridemia, hypertension, and low BMI were independent predictors for CKD.

Conclusions: The presence of metabolic syndrome independently predicts the development of CKD in subjects with type 2 diabetes.

Figures

Figure 1
Figure 1
Cumulative probability of new-onset CKD according to number of metabolic syndrome components.
Figure 2
Figure 2
Percentage of patients with new-onset CKD stratified by medians of waist circumference and BMI.

References

    1. Yoon KH, Lee JH, Kim JW, et al.: Epidemic obesity and type 2 diabetes in Asia. Lancet 368:1681–1688, 2006
    1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414:782–787, 2001
    1. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778, 2005
    1. Chen J, Muntner P, Hamm LL, et al.: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140:167–174, 2004
    1. Costa LA, Canani LH, Lisboa HR, et al.: Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 21:252–255, 2004
    1. Cooper M: Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 352:213–219, 1998
    1. Karter A, Ferrara A, Liu J, et al.: Ethnic disparities in diabetic complications in an insured population. JAMA 287:2519–2527, 2002
    1. Wu AY, Kong NC, de Leon FA, et al.: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 48:1674–1675, 2005
    1. Piwernetz K, Home PD, Snorgaard O, et al.: monitoring the targets of the St. Vincent Declaration and the implementation of quality management in diabetes care: the DIABCARE initiative. Diabet Med 10:371–377, 1993
    1. Tong PC, Kong AP, So WY, et al.: The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III Definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 30:1206–1211, 2007
    1. Ma YC, Zuo J, Chen JH, et al.: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 17:2937–2944, 2006
    1. Grundy SM, Cleeman JI, Daniels SR, et al.: American Heart Association, National Heart, Lung and Blood Institute: diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752, 2005
    1. Thomas GN, Schooling CM, McGhee SM, et al.: Metabolic syndrome increases all-cause and vascular mortality: the Hong Kong Cardiovascular Risk Factor Study. Clin Endocrinol 66:666–671, 2007
    1. Janssen I, Heymsfield SB, Allison DB, et al.: Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous and visceral fat. Am J Clin Nutr 75:683–688, 2002
    1. Janssen I, Katzmarzyk PT, Ross R: Waist circumference and not body mass index explains obesity-related health risk. Am J Clin Nutr 79:379–384, 2004
    1. Lamacchia O, Nicastro V, Camarchio D, et al.: Waist circumference is strongly associated with renal resistive index in normoalbuminuria patients with type 2 diabetes. Am J Nephrol 28:54–58, 2008
    1. Wisse BE: The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 15:2792–2800, 2004
    1. Wong CK, Ho AW, Tong PC, et al.: Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy. J Clin Immunol 28:36–43, 2007
    1. Iseki K, Ikemiya Y, Kinjo K, et al.: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 54:1870–1876, 2004
    1. Boyko EJ, Fujumoto WY, Leonetti DL, et al.: Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care 23:465–471, 2000
    1. Nishida Y, Oda H, Yorioka N: Effect of lipoproteins on mesangial cell proliferation. Kidney Int 71 (Suppl.):S51–S53, 1999
    1. Sandhu S, Wiebe N, Fried LF, et al.: Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016, 2006
    1. Ansquer J, Foucher C, Rattier S, et al.: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485–493, 2005
    1. Tong PC, Kong AP, So WY, et al.: Interactive effect of retinopathy and macroalbuminuria on all-cause mortality, cardiovascular and renal end points in Chinese patients with type 2 diabetes mellitus. Diabet Med 24:741–746, 2007
    1. So WY, Kong AP, Ma RC, et al.: Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 29:2046–2052, 2006

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere